Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:IDYANASDAQ:LYELOTCMKTS:NWBONASDAQ:TYRA On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeIDYAIDEAYA Biosciences$21.67-0.9%$19.56$13.45▼$44.42$1.91B0.041.03 million shs780,090 shsLYELLyell Immunopharma$8.69-9.3%$9.10$7.65▼$45.42$141.86M-0.2669,435 shs229,031 shsNWBONorthwest Biotherapeutics$0.26-3.6%$0.28$0.17▼$0.50$392.28M-1.091.97 million shs2.19 million shsTYRATyra Biosciences$9.23-2.8%$9.76$6.42▼$29.60$504.36M1.07281,309 shs486,061 shs10 "Recession Proof" Stocks That Will Thrive in Any MarketWhich stocks are likely to thrive in today's challenging market? Enter your email address and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceIDYAIDEAYA Biosciences-0.87%-2.30%+13.16%+17.84%-41.86%LYELLyell Immunopharma-9.29%-10.78%+5.98%-24.89%-79.31%NWBONorthwest Biotherapeutics-3.49%-6.44%-3.74%+3.22%-44.62%TYRATyra Biosciences-2.84%-11.51%-5.43%-13.66%-46.34%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationIDYAIDEAYA Biosciences3.611 of 5 stars3.52.00.04.41.41.70.0LYELLyell Immunopharma2.954 of 5 stars2.83.00.00.01.15.01.3NWBONorthwest Biotherapeutics0.1014 of 5 stars0.02.00.00.01.90.00.0TYRATyra Biosciences2.2068 of 5 stars3.51.00.00.02.43.30.0Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceIDYAIDEAYA Biosciences 2.93Moderate Buy$54.27150.45% UpsideLYELLyell Immunopharma 1.50Reduce$20.00130.15% UpsideNWBONorthwest Biotherapeutics 0.00N/AN/AN/ATYRATyra Biosciences 3.00Buy$30.83234.06% UpsideCurrent Analyst Ratings BreakdownLatest NWBO, TYRA, LYEL, and IDYA Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/22/2025IDYAIDEAYA BiosciencesJPMorgan Chase & Co.Subscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOverweight ➝ Overweight$63.00 ➝ $66.005/21/2025TYRATyra BiosciencesPiper SandlerSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOverweight$33.004/16/2025LYELLyell ImmunopharmaHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingNeutral ➝ Neutral$20.00 ➝ $20.003/31/2025TYRATyra BiosciencesHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$30.00 ➝ $30.003/28/2025TYRATyra BiosciencesWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform$30.00(Data available from 6/21/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookIDYAIDEAYA Biosciences$7M271.12N/AN/A$12.25 per share1.77LYELLyell Immunopharma$60K2,144.98N/AN/A$26.21 per share0.33NWBONorthwest Biotherapeutics$1.38M274.14N/AN/A($0.07) per share-3.71TYRATyra BiosciencesN/AN/AN/AN/A$6.78 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateIDYAIDEAYA Biosciences-$274.48M-$3.59N/AN/AN/AN/A-29.28%-27.68%8/5/2025 (Estimated)LYELLyell Immunopharma-$342.99M-$25.00N/AN/AN/A-514,649.22%-73.66%-60.99%8/6/2025 (Estimated)NWBONorthwest Biotherapeutics-$83.78M-$0.07N/A∞N/A-5,757.57%N/A-303.49%8/7/2025 (Estimated)TYRATyra Biosciences-$86.48M-$1.63N/AN/AN/AN/A-26.90%-25.54%8/6/2025 (Estimated)Latest NWBO, TYRA, LYEL, and IDYA EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/15/2025Q1 2025NWBONorthwest BiotherapeuticsN/A-$0.01N/A-$0.01N/A$0.38 million5/13/2025Q1 2025LYELLyell Immunopharma-$3.80-$3.60+$0.20-$0.18N/A$0.01 million5/8/2025Q1 2025TYRATyra Biosciences-$0.49-$0.47+$0.02-$0.47N/AN/A5/6/2025Q1 2025IDYAIDEAYA Biosciences-$0.75-$0.82-$0.07-$0.82$2.10 millionN/A3/31/2025Q4 2024NWBONorthwest BiotherapeuticsN/A-$0.02N/A-$0.02N/A$0.23 million3/27/2025Q4 2024TYRATyra Biosciences-$0.48-$0.43+$0.05-$0.43N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthIDYAIDEAYA BiosciencesN/AN/AN/AN/AN/ALYELLyell ImmunopharmaN/AN/AN/AN/AN/ANWBONorthwest BiotherapeuticsN/AN/AN/AN/AN/ATYRATyra BiosciencesN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioIDYAIDEAYA BiosciencesN/A13.9213.92LYELLyell ImmunopharmaN/A7.497.49NWBONorthwest BiotherapeuticsN/A0.060.06TYRATyra BiosciencesN/A22.7822.78Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipIDYAIDEAYA Biosciences98.29%LYELLyell Immunopharma66.05%NWBONorthwest Biotherapeutics0.04%TYRATyra Biosciences84.14%Insider OwnershipCompanyInsider OwnershipIDYAIDEAYA Biosciences2.50%LYELLyell Immunopharma22.30%NWBONorthwest Biotherapeutics8.70%TYRATyra Biosciences15.20%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableIDYAIDEAYA Biosciences8087.58 million85.39 millionOptionableLYELLyell Immunopharma27014.81 million11.51 millionOptionableNWBONorthwest Biotherapeutics201.46 billion1.33 billionNot OptionableTYRATyra Biosciences2053.09 million45.02 millionOptionableNWBO, TYRA, LYEL, and IDYA HeadlinesRecent News About These CompaniesTyra Biosciences, Inc. (NASDAQ:TYRA) Director Sells $93,575.04 in StockJune 20 at 9:17 PM | marketbeat.comTyra Biosciences, Inc. (NASDAQ:TYRA) Director Sells $70,729.32 in StockJune 17, 2025 | insidertrades.comTyra Biosciences, Inc. (NASDAQ:TYRA) Director Gilla Kaplan Sells 6,814 SharesJune 16, 2025 | marketbeat.comTyra Biosciences, Inc. (NASDAQ:TYRA) Director Sells $154,650.00 in StockJune 16, 2025 | marketbeat.comGilla Kaplan Sells 30,000 Shares of Tyra Biosciences, Inc. (NASDAQ:TYRA) StockJune 16, 2025 | marketbeat.comTyra Biosciences (NASDAQ:TYRA) Shares Down 3% - What's Next?June 16, 2025 | marketbeat.comTyra Biosciences (NASDAQ:TYRA) Shares Up 7.1% - Time to Buy?June 10, 2025 | marketbeat.comTyra Biosciences (NASDAQ:TYRA) Shares Gap Up - Time to Buy?June 9, 2025 | marketbeat.comTyra Biosciences, Inc. (NASDAQ:TYRA) Receives Average Rating of "Buy" from AnalystsJune 6, 2025 | marketbeat.comTyra Biosciences (NASDAQ:TYRA) Trading Down 6% - Here's What HappenedJune 5, 2025 | marketbeat.comTyra Biosciences, Inc. (NASDAQ:TYRA) Sees Significant Growth in Short InterestJune 4, 2025 | marketbeat.comTyra Biosciences, Inc. (NASDAQ:TYRA) Stake Trimmed by Canaan Partners XI LLCJune 3, 2025 | marketbeat.comMillennium Management LLC Increases Stock Position in Tyra Biosciences, Inc. (NASDAQ:TYRA)May 31, 2025 | marketbeat.comTyra Biosciences (NASDAQ:TYRA) Trading 6.1% Higher - Here's WhyMay 30, 2025 | marketbeat.comTyra Biosciences (NASDAQ:TYRA) Now Covered by Piper SandlerMay 23, 2025 | marketbeat.comHC Wainwright Has Optimistic Outlook of TYRA FY2025 EarningsMay 23, 2025 | marketbeat.comEquities Analysts Offer Predictions for TYRA FY2026 EarningsMay 22, 2025 | marketbeat.comVestal Point Capital LP Makes New Investment in Tyra Biosciences, Inc. (NASDAQ:TYRA)May 21, 2025 | marketbeat.comTyra Biosciences to Participate at Upcoming Investor ConferencesMay 12, 2025 | prnewswire.comOne Tyra Biosciences Insider Raised Stake By 284% In Previous YearMay 9, 2025 | finance.yahoo.comTyra Biosciences Reports First Quarter 2025 Financial Results and HighlightsMay 8, 2025 | prnewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeNWBO, TYRA, LYEL, and IDYA Company DescriptionsIDEAYA Biosciences NASDAQ:IDYA$21.67 -0.19 (-0.87%) Closing price 06/20/2025 04:00 PM EasternExtended Trading$21.67 0.00 (0.00%) As of 06/20/2025 04:20 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.IDEAYA Biosciences, Inc., a synthetic lethality-focused precision medicine oncology company, discovers and develops targeted therapeutics for patient populations selected using molecular diagnostics in the United States. The company's products in development include IDE196, a protein kinase C inhibitor that is in Phase 2/3 clinical trials for genetically defined cancers having GNAQ or GNA11 gene mutations; IDE397, a methionine adenosyltransferase 2a inhibitor that is in Phase 1/2 clinical trials for patients with solid tumors having methylthioadenosine phosphorylase gene deletions, such as non-small cell lung, bladder, gastric, and esophageal cancers; IDE161, a poly ADP-ribose glycohydrolase inhibitor that is in Phase 1 clinical trial to treat tumors with homologous recombination deficiency (HRD), and other genetic or molecular signatures; GSK101, a Pol Theta Helicase inhibitor that is in Phase 1 clinical trial for the treatment of tumors with BRCA or other homologous recombination, and HRD mutations; and Werner Helicase inhibitors for tumors with high microsatellite instability. It offers preclinical research programs focused on pharmacological inhibition; DECIPHER dual CRISPR library for synthetic lethality target and biomarker discovery; and INQUIRE chemical library and HARMONY machine-learning engines to enhance its drug discovery platform. The company has strategic alliances with GlaxoSmithKline, Pfizer Inc., Novartis International Pharmaceuticals Ltd., Amgen Inc., Gilead Sciences, Inc., Cancer Research UK, and the University of Manchester. IDEAYA Biosciences, Inc. was incorporated in 2015 and is headquartered in South San Francisco, California.Lyell Immunopharma NASDAQ:LYEL$8.69 -0.89 (-9.29%) Closing price 06/20/2025 04:00 PM EasternExtended Trading$9.10 +0.41 (+4.72%) As of 06/20/2025 06:03 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Lyell Immunopharma, Inc., a clinical-stage cell therapy company, develops T cell reprogramming technologies for patients with solid tumors. The company develops therapies using an ex vivo genetic reprogramming technologies, such as c Jun overexpression and NR4A3 gene knockout, to endow resistance to T cell exhaustion; and an ex vivo epigenetic reprogramming technologies, including Epi R to generate population of T cells with durable stemness, and Stim R, a proprietary synthetic cell mimetic. It is also developing LYL797, a genetically and epigenetically reprogrammed ROR1 chimeric antigen receptor (CAR) T cell product candidate that is in Phase 1 clinical trial for the treatment of various solid tumors; and LYL845, a novel epigenetically reprogrammed tumor-infiltrating lymphocytes product candidate, which is in Phase 1 clinical trial targeting multiple solid tumor indications. In addition, the company's preclinical product candidates include LYL119, a ROR1 CAR T-cell product for the treatment of enhanced cytotoxicity; and second generation TIL product. Lyell Immunopharma, Inc. was incorporated in 2018 and is headquartered in South San Francisco, California.Northwest Biotherapeutics OTCMKTS:NWBO$0.26 -0.01 (-3.56%) As of 06/20/2025 03:59 PM EasternNorthwest Biotherapeutics, Inc., a biotechnology company, develops personalized immune therapies for cancer in the United States and internationally. The company develops its products based on DCVax, a platform technology that uses activated dendritic cells to mobilize a patient's own immune system to attack cancer. Its lead product, DCVax-L, which has completed Phase III clinical trials to treat Glioblastoma multiforme brain cancer. The company also develops DCVax-Direct, which is in Phase I/II clinical trials to treat inoperable solid tumors. The company was founded in 1996 and is headquartered in Bethesda, Maryland.Tyra Biosciences NASDAQ:TYRA$9.23 -0.27 (-2.84%) Closing price 06/20/2025 04:00 PM EasternExtended Trading$9.96 +0.73 (+7.92%) As of 06/20/2025 05:43 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Tyra Biosciences, Inc., a clinical-stage biotechnology company, develops precision medicines for fibroblast growth factor receptor (FGFR) biology in the United States. The company offers SNÅP, a precision medicine platform that enables drug design through iterative molecular snapshots to predict genetic alterations for developing therapies targeting oncology and genetically defined conditions. Its lead product candidate is TYRA-300, which is in Phase 1/2 clinical trials for the treatment of patients with metastatic urothelial carcinoma and other solid tumors. The company is also developing TYRA-300 for skeletal conditions, including achondroplasia, hypochondroplasia, thanatophoric dysplasia, and other FGFR3-driven genetic syndromes; TYRA-200, a candidate in Phase 1 clinical trial for bile duct and solid tumors; and TYRA-430 for the treatment of hepatocellular carcinoma. The company was incorporated in 2018 and is headquartered in Carlsbad, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas New All-Time Highs Coming for Broadcom? Wall Street Says Yes Super Micro Computer Stock's Rally Backed by Strong Financials Forget the Fed: Home Depot Is the Real Gauge of the U.S. Consumer 3 Reasons AMD Could Be the Hottest Stock of the Summer Analysts Keep Boosting Taiwan Semiconductor Stock—Here's Why Robinhood Director Sells Millions, But HOOD Stock Eyes Gains Coinbase Stock Pops as Senate Passes GENIUS Stablecoin Bill Overheated Market? Analysts Watch These Red Flags Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
